Rhythm Pharmaceuticals, Inc. (1RV)
Summary
1RV Chart
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.75 per share a year ago.
Rhythm Pharmaceuticals, Inc. (1RV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rhythm Pharmaceuticals, Inc. ever had a stock split?
Rhythm Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David Meeker CEO | XETRA Exchange | US76243J1051 ISIN |
| US Country | 414 Employees | - Last Dividend | - Last Split | 5 Oct 2017 IPO Date |
Overview
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company with a focus on rare neuroendocrine diseases. Founded in 2008 and based in Boston, Massachusetts, the company originally operated under the name Rhythm Metabolic, Inc. before rebranding to Rhythm Pharmaceuticals, Inc. in October 2015. Through its development of targeted treatments, Rhythm Pharmaceuticals aims to address unmet medical needs within the realm of obesity disorders and other related conditions. The company has entered into several licensing agreements to bolster its research, development, and commercialization efforts, collaborating with notable partners such as LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd.
Products and Services
- IMCIVREE (setmelanotide)
IMCIVREE (setmelanotide) stands as Rhythm Pharmaceuticals' lead product candidate, representing a significant advancement in the treatment of rare forms of obesity. This novel therapeutic targets the melanocortin-4 receptor (MC4R), a critical component in the regulation of hunger and body weight. Its development and testing focus on patients with gene-driven deficiencies linked to obesity, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), leptin receptor (LEPR) deficiency obesity, and conditions such as Bardet-Biedl and Alström syndrome. Currently, IMCIVREE is undergoing Phase 3 clinical trials aimed at evaluating its efficacy in treating heterozygous deficiency obesities related to POMC or LEPR, steroid receptor coactivator 1 (SRC1) deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other disorders associated with the MC4R pathway.
